This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock

On the frontier of some of biopharma's lucrative markets, one competitor's stumble can be a win for one of its rivals. And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to be more dominant in one such market within neuroscience.Here's what happened, and why it's bullish for Lilly's stock.As expected, Johnson & Johnson's third-quarter earnings report had many items of interest to investors; these included adjusted earnings per share (EPS) falling by 9% year over year, reaching $2.42, as well as a couple of changes to its annual outlook. But as always, there were a few tidbits that were notable for their absence: For instance, there was no mention of one of the company's clinical-stage programs for treating Alzheimer's disease.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool